Clinical Trial Detail

NCT ID NCT02404441
Title Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

stomach cancer

Advanced Solid Tumor

anal canal cancer

renal cell carcinoma

esophagus adenocarcinoma

melanoma

lung non-small cell carcinoma

Therapies

Spartalizumab

Age Groups: adult senior

No variant requirements are available.